Compare FCFS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCFS | GKOS |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | 1991 | 2015 |
| Metric | FCFS | GKOS |
|---|---|---|
| Price | $164.76 | $113.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $168.75 | $127.71 |
| AVG Volume (30 Days) | 253.5K | ★ 641.9K |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 27.90 | N/A |
| EPS | ★ 6.92 | N/A |
| Revenue | ★ $3,486,435,000.00 | $469,820,000.00 |
| Revenue This Year | $8.28 | $31.15 |
| Revenue Next Year | $10.44 | $24.15 |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | 3.86 | ★ 30.38 |
| 52 Week Low | $104.99 | $73.16 |
| 52 Week High | $168.36 | $163.71 |
| Indicator | FCFS | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 58.14 |
| Support Level | $154.23 | $109.07 |
| Resistance Level | $168.36 | $115.00 |
| Average True Range (ATR) | 3.66 | 2.76 |
| MACD | 0.33 | -0.95 |
| Stochastic Oscillator | 79.50 | 44.01 |
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.